A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: The interplay between liver metabolising enzymes and transporters is a complex process involving system-related parameters such as liver blood perfusion as well as drug attributes including protein and lipid binding, ionisation, relative magnitude of passive and active permeation. Metabolism- and/or transporter-mediated drug-drug interactions (mDDIs and tDDIs) add to the complexity of this interplay. Thus, gaining meaningful insight into the impact of each element on the disposition of a drug and accurately predicting drug-drug interactions becomes very challenging. To address this, an in vitro-in vivo extrapolation (IVIVE)-linked mechanistic physiologically based pharmacokinetic (PBPK) framework for modelling liver transporters and their interplay with liver metabolising enzymes has been developed and implemented within the Simcyp Simulator(®). METHODS: In this article an IVIVE technique for liver transporters is described and a full-body PBPK model is developed. Passive and active (saturable) transport at both liver sinusoidal and canalicular membranes are accounted for and the impact of binding and ionisation processes is considered. The model also accommodates tDDIs involving inhibition of multiple transporters. Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. RESULTS: The simulated area under the plasma concentration-time curve (AUC), maximum concentration (C max) and the time to reach C max (t max) values of rosuvastatin over the dose range of 10-80 mg, were within 2-fold of the observed data. Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers. CONCLUSION: The results show the utility of the model to integrate a wide range of in vitro and in vivo data and simulate the outcome of clinical studies, with implications for their design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · cited 1×
“becoming evident that transporter-mediated drug–drug interactions (tDDIs) may pose challenges for regulatory approval and clinical practice [1, 2].”
BackgroundRodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776 · cited 4×
“M. Jamei1*, F. Bajot1,†, S. Neuhoff1, Z. Barter1, J. Yang1,‡, A. Rostami-Hodjegan 1,2 and K. Rowland-Yeo1 1Simcyp Limited, Blades Enterprise Centre, Sheffield, UK; 2 Centre of Applied Pharmacokinetic Research, the School of Pharmacy and Pharmaceutical Sciences, the University of Manchester, Manchester, UK † Current po…”
BackgroundMethodInfluentialPoulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10005 · Cited by 568 · cited 2×
“They predicted fuIW using the method by Poulin and Theil [31, 32] and fuEW using the method by Rodgers and Rowland [30, 34].”
BackgroundMethodThe Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533 · cited 1×
“The model that is incorporated within the Simcyp Population Based Simulator [24] allows investigation of metabolism and”
MethodSelf-citationBarter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459 · cited 1×
“the hepatocytes per gram of liver [36], LiverWt is the liver weight [37] and REF is the relative expression factor, which can also be replaced by a relative activity factor (RAF), and 60 9 10 is the unit change to convert the CLint,T to L/h.”
BackgroundSelf-citationPopulation-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
Self-citationRostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331 · cited 2×
“Indeed, it can only increase our understanding of the drug response and its variability [23].”
BackgroundSelf-citationMetabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286 · cited 7×
“4 lL/min/mg protein) was assigned as the metabolism component for human liver microsomes (HLM) based on previously published data [8, 13, 53].”
MethodInfluentialElsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
Clinical pharmacokinetics of statins
Garcia, M. J., Reinoso, R. F., Sanchez Navarro, A., & Prous, J. R. (2003) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2003.25.6.769652 · Cited by 121
Barton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
Cited by
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Herland, A., Maoz, B. M., Das, D., Somayaji, M. R., Prantil-Baun, R., Novak, R., Cronce, M., Huffstater, T., Jeanty, S. S. F., Ingram, M., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0498-9 · Cited by 500
Metadata
- Authors
- Jamei, M., Bajot, F., Neuhoff, S., Barter, Z., Yang, J., Rostami-Hodjegan, A., & Rowland-Yeo, K.
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-07-24
- Volume
- 53
- Issue
- 1
- Pages
- 73-87
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2104778855
- Cited by
- 163
- References
- 11
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.